Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Who May Qualify: - Patients with HCC for whom TARE decision was made at the MDT - Patients ≥ 18 years of age - Diagnosis of HCC based on imaging (EASL guidelines) and confirmed histologically - At least one target lesion to be treated by radioembolisation, naïve to any previous treatment - Child-Pugh Class \< B8 - Eastern Cooperative Oncology Group (ECOG) ≤ 2 - Life expectancy ≥ 3 months - Available baseline imaging (multiphasic CT), performed within 6 weeks before the beginning of TARE Who Should NOT Join This Trial: - Patient with contraindication to MRI - Patient with contraindication to 18F-choline : potential hypersensitivity to the product or to any excipients - Non-adequate bone marrow, liver and renal function within 15 days prior to work-up as assessed by the following laboratory tests: - Hemoglobin ≤ 8.0 g/Dl - Platelet count \< 50,000/ mm3 - Total bilirubin \> 3 mg/dL (or \> 51 µmol/ L). - Prothrombin time ≤ 50% - Glomerular Filtration Rate (GFR) \< 35 mL/min/1.73 m2 - Infiltrating tumor more than 70% of the liver - Prior liver transplantation - Initial prescription for SIRT and concomitant systemic treatment - Patient refusal to give written and willing to sign a consent form - No affiliation to a social security regimen or CMU - Patient under State Medical Aid - Known pregnancy or breastfeeding women - Patient deprived of freedom, subject under a legal protective measure - Any significant medical, psychiatric, or surgical condition that is uncontrolled and could endanger the subject's safety or limit adherence to the study's objectives and assessments Always talk to your doctor about whether this trial is right for you.